一分钟看懂
这是一项关于乳腺癌的I 期 / II 期研究，登记的药物或干预包括AZD8205；AZD8205 and AZD2936 (Rilvegostomig)；AZD8205 and AZD5305 (saruparib)；AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)；AZD8，当前状态为招募中。登记地点显示中国北京、长沙、重庆、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
AZD8205；AZD8205 and AZD2936 (Rilvegostomig)；AZD8205 and AZD5305 (saruparib)；AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)；AZD8205 in combination with AZD9574；AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 北京
- Research Site · 长沙
- Research Site · 重庆
- Research Site · 广州
- Research Site · 昆明
- Research Site · 山东省
公开的入选条件
- * Age ≥ 18 years
- * Relapsed/metastatic solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerab
- * Measurable disease per RECIST v1.1
- * Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
- * Life expectancy ≥ 12 weeks
- * Adequate bone marrow, hepatic, and renal function as defined in the protocol
- Additional Inclusion Criteria For Sub-Study 1 Part A:
- • Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC or endometrial cancer
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05123482；登记信息更新于 2026-09-11。